Steroide-induced diabetes, a common clinical problem in medicine without evidence-based guidelines;Diabète cortico-induit, une entitéfréquente sans prise en charge standardisée

Revue Medicale Suisse

Volumn 8, Issue 336, 2012, Pages 800-805

  Genolet, P ^a   Petite, C ^b   Petignat, P A ^a  

^a CHCVs   (Switzerland)

^b Endocrinologue FMH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; INSULIN; ANTIDIABETIC AGENT;

DIABETES MELLITUS; DRUG INDUCED DISEASE; EVIDENCE BASED MEDICINE; HUMAN; HYPERGLYCEMIA; PRACTICE GUIDELINE; REVIEW; ARTICLE; CHEMICALLY INDUCED DISORDER; RISK FACTOR;

GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84862318370     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. *Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011;335:2-13.
2. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988;4:17-30. (Pubitemid 18072099)
3. **Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-74.
4. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505. (Pubitemid 29400386)
5. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol 2006;4:479-83. (Pubitemid 44698157)
6. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids. New mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
7. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101. (Pubitemid 24018107)
8. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728-9. (Pubitemid 44912208)
9. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011;34:412-7.
10. Donihi AC, Raval D, Saul M, Korytkowski MT, De-Vita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006;12:358-62. (Pubitemid 44717593)
11. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplan- tation 1997;64:979-83. (Pubitemid 27446762)
12. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43. (Pubitemid 35346616)
13. Brindley DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int J Obes Relat Metab Dis ord 1995;19(Suppl.1):S69-75.
14. Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998;29:259-62. (Pubitemid 28458273)
15. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
16. Farrokhi F, Smiley D, Umpierrez GE. Glycemic control in non-diabetic critically ill patients. Best Pract Res Clin Endocrinol Metab 2011;25:813-24.
17. van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003;31:359-66. (Pubitemid 36232926)
18. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl.1):S11-61.
19. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-31.